InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
2
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-24.2%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the complete record of transactions filed by Waksal Harlan, 董事长兼首席执行官. Officer active across 4 companies, notably Kadmon Holdings, Inc.. Cumulatively, 6 reports have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €69k. History available since 13 May 2021. The latest transaction was filed on 18 March 2024 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Waksal Harlan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
30,000 股Common StockSEC:0001449008-26-000004:0
275,000 股0Common StockSEC:0000950170-24-034350:0
25,000 股@ US$2.96387.0% 占其流量Common StockSEC:0000950170-23-063137:0
标准退出：2024年2月8日 (T+90)
236,966 股@ €3.898100.0% 占其流量Common StockSEC:0000899243-22-014737:0
标准退出：2022年7月11日 (T+90)
177,945 股@ US$9.5095.2% 占其流量Common StockSEC:0001104659-21-136412:0
25,000 股@ US$3.55914.8% 占其流量Common StockSEC:0001593968-21-001330:0
6 条申报中的 6 条
About Waksal Harlan
Harlan Waksal serves as President & CEO and Executive Chair at Kadmon Holdings, Inc. and Lyra Therapeutics, Inc. In this role, he oversees the operations and strategy of both companies. His experience in the biopharmaceutical sector allows him to make significant contributions to growth and innovation.
